- Home
- PCSA
as 02-04-2025 1:37pm EST
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | HANOVER |
| Market Cap: | 2.7M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 452.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $3.31 | Next Earning Date: | 03-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Processa Pharmaceuticals Inc. (PCSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young David | PCSA | Pres. Research & Development | Jan 27 '25 | Buy | $0.80 | 124,500 | $99,288.75 | 205,405 | |
| Lin Patrick | PCSA | Chief Business - Strategy Off | Jan 27 '25 | Buy | $0.80 | 43,500 | $34,691.25 | 43,500 | |
| Ng George K | PCSA | Chief Executive Officer | Jan 27 '25 | Buy | $0.80 | 87,200 | $69,542.00 | 87,200 |
Latest Processa Pharmaceuticals Inc. News
PCSA Breaking Stock News: Dive into PCSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
8 days ago
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire
3 months ago
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
GlobeNewswire
4 months ago
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
GlobeNewswire
5 months ago
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
GlobeNewswire
5 months ago
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
GlobeNewswire
6 months ago
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
GlobeNewswire
6 months ago
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Compare PCSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCSA Processa Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.